BioCatalyst

BT5528, Nivolumab — catalyst calendar

1 verified catalyst event(s) referencing BT5528, Nivolumab, each linked to its official source. Verified as of 2026-10-17.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-31
in 3mo
ESTIMATED
 READOUT
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Ex
Phase 1/2 · Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
 BicycleTx Limited BT5528, Nivolumab ClinicalTrials.gov ↗
✓ Source-checked 2026-10-17
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.